DK1326858T3 - Piperidinforbindelser som anti-allergiske midler - Google Patents

Piperidinforbindelser som anti-allergiske midler

Info

Publication number
DK1326858T3
DK1326858T3 DK01983968T DK01983968T DK1326858T3 DK 1326858 T3 DK1326858 T3 DK 1326858T3 DK 01983968 T DK01983968 T DK 01983968T DK 01983968 T DK01983968 T DK 01983968T DK 1326858 T3 DK1326858 T3 DK 1326858T3
Authority
DK
Denmark
Prior art keywords
piperidine compounds
allergic agents
allergic
agents
piperidine
Prior art date
Application number
DK01983968T
Other languages
Danish (da)
English (en)
Inventor
Robert G Aslanian
Neng-Yang Shih
Pauline C Ting
Michael Y Berlin
Stuart B Rosenblum
Kevin D Mccormick
Wing C Tom
Christopher W Boyce
Pietro Mangiaracina
Mwangi Wa Mutahi
John J Piwinski
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1326858T3 publication Critical patent/DK1326858T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
DK01983968T 2000-10-17 2001-10-15 Piperidinforbindelser som anti-allergiske midler DK1326858T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24090100P 2000-10-17 2000-10-17

Publications (1)

Publication Number Publication Date
DK1326858T3 true DK1326858T3 (da) 2006-05-08

Family

ID=22908389

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01983968T DK1326858T3 (da) 2000-10-17 2001-10-15 Piperidinforbindelser som anti-allergiske midler
DK05009405T DK1571145T3 (da) 2000-10-17 2001-10-15 Substitueret piperidinforbindelser til anvendelse som H3 histaminreceptor-antagonister

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05009405T DK1571145T3 (da) 2000-10-17 2001-10-15 Substitueret piperidinforbindelser til anvendelse som H3 histaminreceptor-antagonister

Country Status (30)

Country Link
US (3) US6720328B2 (de)
EP (2) EP1571145B1 (de)
JP (2) JP4093859B2 (de)
KR (1) KR100567266B1 (de)
CN (2) CN1803795B (de)
AR (1) AR035497A1 (de)
AT (2) ATE312833T1 (de)
AU (2) AU1535502A (de)
BR (1) BR0114754A (de)
CA (1) CA2424664C (de)
CY (2) CY1105227T1 (de)
DE (2) DE60137461D1 (de)
DK (2) DK1326858T3 (de)
EC (1) ECSP034559A (de)
ES (2) ES2320008T3 (de)
HK (1) HK1052935B (de)
HU (1) HUP0303835A3 (de)
IL (1) IL155031A0 (de)
MX (1) MXPA03003529A (de)
NO (1) NO325997B1 (de)
NZ (1) NZ524857A (de)
PE (1) PE20020507A1 (de)
PL (1) PL361978A1 (de)
PT (1) PT1571145E (de)
RU (2) RU2301231C2 (de)
SI (1) SI1326858T1 (de)
SK (1) SK4672003A3 (de)
TW (2) TWI258474B (de)
WO (1) WO2002032893A2 (de)
ZA (1) ZA200302521B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
MXPA03008356A (es) * 2001-03-13 2003-12-11 Schering Corp Compuestos del tipo no imidazol como antagonistas de histamina h3.
AR036881A1 (es) * 2001-10-15 2004-10-13 Schering Corp Un proceso para la preparacion de 4-(piperidil)(2-piridil)metanona-(e)-o-metiloxima y sales
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
MXPA04010172A (es) 2002-04-18 2005-02-03 Schering Corp 1-(4-piperidinil)benzimidazolonas como antagonistas de histamina h3).
DE60319813T2 (de) * 2002-04-18 2009-04-23 Schering Corporation 1-(4-piperidinyl)benzimidazole als histamin h3 antagonisten
DE60309598T2 (de) * 2002-06-24 2007-09-13 Schering Corp. Als histamin-h3-antagonisten geeignete indolderivate
AR041137A1 (es) 2002-09-04 2005-05-04 Pharmacopeia Drug Discovery Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
MXPA05011352A (es) 2003-04-23 2005-11-28 Glaxo Group Ltd Derivados de piperazina y su uso para el tratamiento de enfermedades neurologicas y psiquiatricas.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005014571A1 (en) * 2003-07-18 2005-02-17 Glaxo Group Limited Substituted piperidines as histamine h3 receptor ligands
US20060030550A1 (en) * 2004-08-04 2006-02-09 Lithgow Theodore L Pharmaceutical formulations
GB0420831D0 (en) * 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
EP1896453B1 (de) * 2005-06-20 2009-12-02 Schering Corporation Kohlenstoffgebundene substituierte piperidine und derivate daraus als histamin-h3-antagonisten
JP2008546784A (ja) 2005-06-20 2008-12-25 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体
US7332604B2 (en) * 2005-09-20 2008-02-19 Schering Corporation 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine
JP2009521451A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用な置換アニリン誘導体
EP1976848A2 (de) * 2005-12-21 2008-10-08 Schering Corporation Phenoxypiperidine und analoge davon als histamin-h3-antagonisten
BRPI0620386A2 (pt) * 2005-12-21 2011-12-20 Schering Corp composição compreendendo a combinação de um antagonista de h3/agonista inverso e um supressor de apetite e uso da referida composição
CA2634940A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
BRPI0706623A2 (pt) 2006-01-18 2011-04-12 Schering Corp moduladores de receptor canabinóide
CN101674831A (zh) * 2007-03-02 2010-03-17 先灵公司 用于治疗糖尿病或疼痛的哌啶基哌啶和哌嗪基哌啶
EP2548874A3 (de) * 2007-06-28 2013-05-15 Intervet International B.V. Substituierte Piperazine als CB1-Antagonisten
AU2008312638B2 (en) * 2007-10-17 2013-05-16 Sanofi-Aventis Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
CA2702834C (en) * 2007-10-17 2013-01-15 Sanofi-Aventis Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof
CN101903341B (zh) * 2007-10-17 2012-10-03 赛诺菲-安万特 取代的n-苯基-联吡咯烷脲及其治疗用途
MY151348A (en) * 2007-10-17 2014-05-15 Sanofi Aventis Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
WO2009089134A1 (en) 2008-01-04 2009-07-16 Src, Inc. Methods for measuring a patint response upon administration of a drug and compositions thereof
EP2318388A2 (de) 2008-07-23 2011-05-11 Schering Corporation Tricyclische spirocyclusderivate und verfahren zu deren verwendung
CA2739491A1 (en) 2008-10-16 2010-04-22 Schering Corporation Azine derivatives and methods of use thereof
EP2379564A1 (de) 2008-12-19 2011-10-26 Schering Corporation Bicyclische heterocyclische derivate und verfahren zu deren verwendung
WO2010071822A1 (en) 2008-12-19 2010-06-24 Schering Corporation Piperidine and piperazine derivatives and methods of use thereof
JP2012524809A (ja) * 2009-04-22 2012-10-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ モノアシルグリセロールリパーゼ阻害剤としての複素芳香族及び芳香族ピペラジニルアゼチジニルアミド類
EP2443134A2 (de) 2009-06-16 2012-04-25 Schering Corporation Neue [3,2-c]heteroarylsteroide als glucocorticoidrezeptoragonisten, zusammensetzungen und verwendung
CA2771822C (en) 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
EP2527340B1 (de) * 2010-01-22 2016-08-17 Taiho Pharmaceutical Co., Ltd. Piperazinverbindung mit pgds-inhibierender wirkung
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CN105315267B (zh) * 2014-07-30 2019-06-04 江苏恩华药业股份有限公司 一种酰胺类衍生物及其应用
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
SG11201900515PA (en) 2016-07-21 2019-02-27 Biogen Ma Inc Succinate forms and compositions of bruton's tyrosine kinase inhibitors
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CN110105263A (zh) * 2019-05-13 2019-08-09 常州大学 一种阿米卡星中间体的合成方法
CA3124579C (en) 2020-07-15 2026-03-31 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
JP2023534810A (ja) 2020-07-15 2023-08-14 シャバー リサーチ アソシエイツ エルエルシー 急性痛の処置並びに胸やけの重症度及び／又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920701167A (ko) 1989-07-07 1992-08-11 에릭 에스. 딕커 약제학적 활성 화합물
US5807872A (en) 1992-12-16 1998-09-15 Schering Corporation Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring
US5633250A (en) 1991-12-18 1997-05-27 Schering Corporation Imidazoylalkyl substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
NZ246441A (en) 1991-12-18 1996-02-27 Schering Corp Imidazol or imidazolalkyl substituted with a 4 or 5 membered nitrogen containing heterocycle, preparation and pharmaceutical compositions thereof
NZ276883A (en) 1993-11-15 1998-08-26 Schering Corp 1h-imidazol-4-yl)alkyl]benzene derivatives
JPH11513991A (ja) 1995-11-17 1999-11-30 ヘキスト・マリオン・ルセル・インコーポレイテツド アレルギー性疾患の治療に有用な置換４−（１ｈ−ベンズイミダゾル−２−イル−アミノ）ピペリジン
SK20099A3 (en) 1996-08-16 2000-08-14 Schering Corp Treatment of upper airway allergic responses with a combination of histamine receptor antagonists
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
US6034251A (en) 1997-11-07 2000-03-07 Schering Corporation Phenyl-alkyl-imidazoles
WO1999024405A1 (en) 1997-11-07 1999-05-20 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
US5990147A (en) 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
RU2135454C1 (ru) * 1998-03-30 1999-08-27 Сосна Михаил Хаймович Переработка природного газа с получением метанола
JP2002527381A (ja) * 1998-10-09 2002-08-27 シェーリング コーポレイション アレルギー性疾患を処置するための組成物および方法
US6100279A (en) 1998-11-05 2000-08-08 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
MXPA03008356A (es) 2001-03-13 2003-12-11 Schering Corp Compuestos del tipo no imidazol como antagonistas de histamina h3.
MXPA04010172A (es) * 2002-04-18 2005-02-03 Schering Corp 1-(4-piperidinil)benzimidazolonas como antagonistas de histamina h3).
US7105505B2 (en) * 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
DE60309598T2 (de) * 2002-06-24 2007-09-13 Schering Corp. Als histamin-h3-antagonisten geeignete indolderivate
US20040198743A1 (en) * 2003-01-31 2004-10-07 Schering Corporation Methods for treating allergic skin and allergic ocular conditions using combinations of histamine receptor antagonists

Also Published As

Publication number Publication date
HK1081182A1 (en) 2006-05-12
DE60115937D1 (de) 2006-01-19
SK4672003A3 (en) 2003-11-04
TWI292399B (en) 2008-01-11
US20030045519A1 (en) 2003-03-06
HUP0303835A3 (en) 2009-08-28
CN1469873A (zh) 2004-01-21
EP1326858A2 (de) 2003-07-16
ES2320008T3 (es) 2009-05-18
RU2007104096A (ru) 2008-08-10
NO20031744D0 (no) 2003-04-15
KR100567266B1 (ko) 2006-04-03
CA2424664C (en) 2008-12-23
CN1243751C (zh) 2006-03-01
TW200510368A (en) 2005-03-16
CA2424664A1 (en) 2002-04-25
EP1326858B1 (de) 2005-12-14
EP1571145B1 (de) 2009-01-14
CN1803795B (zh) 2010-05-12
NO20031744L (no) 2003-06-14
AU2002215355B2 (en) 2006-09-14
IL155031A0 (en) 2003-10-31
US20080119487A1 (en) 2008-05-22
NZ524857A (en) 2004-12-24
ATE312833T1 (de) 2005-12-15
MXPA03003529A (es) 2003-08-07
WO2002032893A3 (en) 2002-08-22
PE20020507A1 (es) 2002-06-25
HUP0303835A2 (hu) 2004-03-01
KR20030036931A (ko) 2003-05-09
US7300941B2 (en) 2007-11-27
SI1326858T1 (sl) 2006-04-30
RU2301231C2 (ru) 2007-06-20
AR035497A1 (es) 2004-06-02
ATE420863T1 (de) 2009-01-15
DK1571145T3 (da) 2009-05-04
HK1052935A1 (en) 2003-10-03
JP4093859B2 (ja) 2008-06-04
PL361978A1 (en) 2004-10-18
EP1571145A1 (de) 2005-09-07
CY1105227T1 (el) 2010-03-03
NO325997B1 (no) 2008-09-01
US20040097513A1 (en) 2004-05-20
TWI258474B (en) 2006-07-21
JP2004511553A (ja) 2004-04-15
DE60137461D1 (de) 2009-03-05
ZA200302521B (en) 2004-06-30
CY1110262T1 (el) 2015-01-14
BR0114754A (pt) 2003-07-01
US6720328B2 (en) 2004-04-13
ES2250500T3 (es) 2006-04-16
DE60115937T2 (de) 2006-06-29
CN1803795A (zh) 2006-07-19
HK1052935B (en) 2006-05-19
JP2007145866A (ja) 2007-06-14
ECSP034559A (es) 2003-06-25
WO2002032893A2 (en) 2002-04-25
PT1571145E (pt) 2009-04-07
AU1535502A (en) 2002-04-29

Similar Documents

Publication Publication Date Title
NO20031001D0 (no) Polyarylkarboksamider nyttige som lipidsenkende midler
NO20026195D0 (no) Substituerte-triazolopyrimidiner som anticancer midler
IS6561A (is) Bensóamíð píperidín efnasambönd sem P-efnis mótlyf
NO20026196L (no) Kinazolinditosylatsalt-forbindelser
DK1619192T3 (da) Arylkondeserede azapolycykliske forbindelser
NO20032585L (no) ABCA-1 forhoyende forbindelser
NO20042955L (no) Substituerte fenylaftalener som estrogene midler
NO20032390L (no) Serotonerge midler
NO20032272D0 (no) Bifenylkarboksamider nyttige som lipidsenkende midler
NO20030276D0 (no) Fremgangsmåte
NO20022985L (no) Substituerte aminometyl-fenyl-cykloheksanderivater
PT1299356E (pt) Novos compostos
AR028220A1 (es) Novedosos compuestos
ATE372338T1 (de) Deshalogenverbindungen
NO20030303D0 (no) Kalsilytiske forbindelser
NO20022983L (no) Aminometyl-fenyl-cykloheksanonderivater
NO20023508D0 (no) Kalsilyttiske forbindelser
NO20031837L (no) Kalsilytiske forbindelser
AR028399A1 (es) Nuevos compuestos
IS8574A (is) Ný efnasambönd
SE0002788D0 (sv) New compounds
FI20050832L (fi) Uudet yhdisteet
SE0000263D0 (sv) New compounds
SE0003640D0 (sv) New compounds
AR027949A1 (es) Novedosos compuestos